Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity

American Journal of Nephrology

Volumn 26, Issue 4, 2006, Pages 400-407

  Shihab, Fuad S ^a   Bennett, William M ^b   Yi, Hong ^a   Andoh, Takeshi F ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Legacy Solid Organ and Cellular Transplantation Services   (United States)

Author keywords

Apoptosis; Connective tissue growth factor; Cyclosporine; Nephrotoxicity; Sirolimus

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORIN; MESSENGER RNA; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; NEPHROTOXICITY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CHRONIC DISEASE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GENE EXPRESSION; IMMEDIATE-EARLY PROTEINS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEPHROSIS; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33748693147     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095300     Document Type: Article

References (35)

1. Leask A, Abraham DJ: The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003;81:355-363.
2. Perbal B: CCN proteins: multifunctional signaling regulators. Lancet 2004;363:62-64.
3. Wahab NA, Mason RM: Connective tissue growth factor and renal diseases: some answers, more questions. Curr Opin Nephrol Hypertens 2004;13:53-58.
4. Leask A, Denton CP, Abraham DJ: Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol 2004;122:1-6.
5. Grotendorst GR: Connective tissue growth factor: a mediator of TGF-β action on fibroblasts. Cytokine Growth Factor Rev 1997;8:171-179.
6. Leask A, Abraham DJ: The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003;81:355-363.
7. Zhou G, Li C, Cai L: Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor-β-independent pathway. Am J Pathol 2004;165:2033-2043.
8. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A: Tumor necrosis factor-α suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-15225.
9. Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP, King GL: Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidinylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem 2000;275:40725-40731.
10. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D: Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241-250.
11. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M: Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003;108:1499-1505.
12. Ruperez M, Ruiz-Ortega M, Esteban V, et al: Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003;163:1937-1947.
13. Andersen S, van Nieuwenhoven FA, Tarnow L, Rossing P, Rossing K, Wieten L, Goldschmeding R, Parving HH: Reduction of urinary connective tissue growth factor by losartan in type 1 patients with diabetic nephropathy. Kidney Int 2005;67:2325-2329.
14. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557-565.
15. Chueh SCJ, Kahan BD: Clinical application of sirolimus in renal transplantation: an update. Transplant Int 2005;18:261-277.
16. Kahan BD: Sirolimus-based immunosuppression: present state of the art. J Nephrol 2004;17:32-39.
17. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Giout-Paquet M, Scarola JA, Neylan JF: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004;15:809-817.
18. Marti HP, Frey FJ: Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant 2005;20:13-15.
19. Andoh TF, Lindsley J, Franceschini N, Bennett WM: Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996;62:311-316.
20. 1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004;65:1262-1271.
21. Rosen S, Greenfeld Z, Brezis M: Chronic cyclosporine-induced nephropathy in the rat. Transplantation 1990;49:445-452.
22. Burdmann EA, Andoh TF, Nast CC, Evan A, Connors BA, Coffman T, Lindsley J, Bennett WM: Prevention of experimental cyclosporine-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995;269:F491-F499.
23. Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, Vapaatalo H, Muller D, Ganten D, Luft F, Mervaala E: Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 2003;163:355-366.
24. 1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996;49:1141-1151.
25. Moussad EE, Brigstock DR: Connective tissue growth factor: what's in a name? Mol Genet Metab 2000;71:276-292.
26. Brigstock DR: The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 1999;20:189-206.
27. Crean JK, Finlay D, Murphy M, Moss C, Godson C, Martin F, Brady HR: The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem 2002;277:44187-44194.
28. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001;38:635-638.
29. Bobik A: Hypertension, transforming growth factor-β, angiotensin II and kidney disease. J Hypertens 2004;22:1389-1395.
30. 1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997;52:660-673.
31. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 2000;103:253-262.
32. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M: Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-β-independent mechanism. Circulation 2005;111:2509-2517.
33. Kondo S, Kubota S, Eguchi T, Hattori T, Nakanishi T, Sugahara T, Takigawa M: Characterization of a mouse ctgf 3′-UTR segment that mediates repressive regulation of gene expression. Biochem Biophys Res Commun 2000;278:119-124.
34. Hishikawa K, Oemer BS, Nakati T: Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem 2001;276:16797-16803.
35. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C: Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005;80:1198-1203.